Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.
Verve Therapeutics, Inc. (Nasdaq: VERV) is a cutting-edge biotechnology company headquartered in Cambridge, Massachusetts. With a mission to protect the world from heart disease, Verve is pioneering a transformative approach in cardiovascular care. The company leverages two major breakthroughs in 21st-century biomedicine—human genetics analysis and gene editing—to create life-changing therapies for coronary heart disease.
Verve Therapeutics is focused on developing single-course gene editing medicines to permanently lower LDL cholesterol and triglyceride levels in adults, thereby reducing the risk of coronary heart disease. Their innovative treatments are designed to be administered once in a lifetime, offering a potential shift from chronic disease management to a one-time cure.
Founded by leading experts in cardiovascular medicine, human genetics, and gene editing, Verve has garnered substantial support from top-tier investors, including GV (formerly Google Ventures), Arch Venture Partners, and others. The company was recognized as a '2020 Best Places to Work' by the Boston Business Journal, highlighting its positive workplace culture and innovative environment.
Verve's flagship programs include VERVE-101, VERVE-102, and VERVE-201, each targeting genes validated for their role in lowering low-density lipoprotein cholesterol (LDL-C). Specifically, VERVE-101 and VERVE-102 aim to permanently deactivate the PCSK9 gene, initially targeting patients with heterozygous familial hypercholesterolemia (HeFH) and eventually expanding to treat patients with atherosclerotic cardiovascular disease (ASCVD) who have not reached LDL-C goals using traditional therapies. Meanwhile, VERVE-201 targets the ANGPTL3 gene, focusing on patients with homozygous familial hypercholesterolemia (HoFH) and refractory hypercholesterolemia.
Recent milestones for Verve Therapeutics include the first human proof-of-concept data for in vivo base editing from the ongoing heart-1 phase 1b clinical trial of VERVE-101. This study demonstrated dose-dependent reductions in disease-causing LDL-C in patients with HeFH. The company is also progressing with the heart-2 phase 1b clinical trial for VERVE-102 and plans to launch a phase 1b trial for VERVE-201 in the latter half of 2024.
In terms of financial performance, Verve maintains a solid cash position, with $624.0 million in cash and marketable securities as of December 31, 2023. This robust financial standing is augmented by strategic partnerships, including a significant collaboration with Eli Lilly, which involved a private placement and potential milestone payments up to $465 million.
Under the leadership of CEO Sekar Kathiresan, M.D., Verve is pushing the boundaries of cardiovascular disease treatment. The company's relentless commitment to scientific excellence and patient care positions it as a potential game-changer in the field of genetic medicine.
Verve Therapeutics reported updates on its clinical pipeline and financial results for Q4 and full-year 2022. The heart-1 clinical trial of VERVE-101 is ongoing in New Zealand and the UK, with initial data expected in H2 2023. The company holds $554.8 million in cash, enough to fund operations into mid-2025. Collaboration revenue reached $1.0 million in Q4 2022, while R&D expenses increased to $37.3 million. The net loss was $41.1 million for the quarter. Positive regulatory advancements include the recent Innovation Passport award for VERVE-101 by the UK MHRA, aiming to accelerate patient access.
Verve Therapeutics has announced that its investigational gene editing medicine, VERVE-101, has received the Innovation Passport designation from the UK’s MHRA for treating heterozygous familial hypercholesterolemia (HeFH). This designation aims to expedite the development and patient access to innovative treatments. VERVE-101 is designed to permanently turn off the PCSK9 gene in the liver, potentially lowering LDL cholesterol levels significantly. The ongoing Heart-1 clinical trial, assessing VERVE-101’s safety and efficacy, is expected to produce initial data in late 2023, which marks a critical step for the company and its mission to transform cardiovascular care.
Verve Therapeutics, a clinical-stage biotechnology firm, will have its CEO, Sekar Kathiresan, present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 4:30 p.m. PT in San Francisco. The live presentation will be accessible via webcast, archived for 30 days. Verve focuses on innovative gene editing therapies for cardiovascular disease, notably through programs VERVE-101 and VERVE-201, aimed at lowering LDL cholesterol levels to combat heart disease.
Verve Therapeutics, a clinical-stage biotechnology firm, focuses on innovative gene editing therapies for cardiovascular diseases. CEO Sekar Kathiresan will present at two investor conferences: the Jefferies London Healthcare Conference on November 15, 2022, and the Evercore ISI Virtual HealthCONx Conference on November 29, 2022. These events will be broadcast live and archived for 60 days. Notably, their programs VERVE-101 and VERVE-201 aim to lower LDL cholesterol levels by targeting specific genes, potentially transforming chronic care into a single treatment solution.
Verve Therapeutics announced that the FDA has placed a hold on its IND application for VERVE-101, an investigational gene editing treatment for heterozygous familial hypercholesterolemia (HeFH). Despite this, dosing has been completed in the first cohort of the heart-1 clinical trial in New Zealand and the U.K., with no adverse events reported. The company is well-capitalized with $550.7 million in cash, enough to fund operations into the second half of 2025. R&D expenses rose to $35.2 million, contributing to a net loss of $45.2 million for Q3 2022.
Verve Therapeutics recently received the Paul Dudley White International Scholar Award from the American Heart Association for the highest-ranked abstract from the U.S. at Scientific Sessions 2022. This recognition is based on preclinical results for VERVE-101, a gene editing medicine targeting PCSK9 to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia (HeFH). The study in non-human primates showed significant reductions in both PCSK9 protein and LDL cholesterol levels, with no germline transmission. The data will be presented at the AHA meeting from November 5-7, 2022.
Verve Therapeutics, a biotechnology company focused on cardiovascular disease, has announced its participation in several investor conferences. Key events include the Guggenheim 2022 Nantucket Therapeutics Conference on September 28, the Jefferies Cell and Genetic Medicine Summit on September 29, the Chardan 6th Annual Genetic Medicine Conference on October 4, the BMO Virtual Biopharma Spotlight Series on October 6, and the Truist Securities Genetic Medicine Summit on October 20.
Live webcasts will be available on the company’s investor website for 60 days post-event.
Verve Therapeutics has received clearance for its Clinical Trial Authorization (CTA) application from the UK Medicines and Healthcare products Regulatory Agency for VERVE-101, aimed at treating heterozygous familial hypercholesterolemia (HeFH). This achievement marks the second regulatory clearance for VERVE-101, which is currently in the heart-1 clinical trial in New Zealand and set to begin patient enrollment in the UK. The trial aims to assess the safety and tolerability of VERVE-101 and gather interim clinical data in 2023, showcasing Verve's commitment to innovating cardiovascular disease care.
Verve Therapeutics has announced new preclinical data for its gene editing candidate, VERVE-201, aimed at treating homozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease. This candidate targets the ANGPTL3 gene in the liver, significantly impacting cholesterol metabolism. Promising results showed potent, on-target editing in human liver cells and substantial reductions in ANGPTL3 protein levels in non-human primates. The company plans to present this data at the European Society of Cardiology 2022 Congress on August 29, 2022, and anticipates moving towards clinical trials in 2024.
Verve Therapeutics reported significant advancements, including over $300 million added to its balance sheet, supporting operations well into the second half of 2025.
VERVE-101, aimed at treating heterozygous familial hypercholesterolemia, initiated patient dosing with interim clinical data expected in 2023. Regulatory clearances in the UK and US are anticipated soon.
The company also nominated VERVE-201 for ANGPTL3 treatment, with upcoming data presentations and IND-enabling studies in the pipeline. Additionally, new board members were appointed to bolster strategic growth.
FAQ
What is the current stock price of Verve Therapeutics (VERV)?
What is the market cap of Verve Therapeutics (VERV)?
What is Verve Therapeutics' main focus?
Where is Verve Therapeutics headquartered?
What are the key programs of Verve Therapeutics?
Who are some of Verve Therapeutics' investors?
What recent milestone has Verve Therapeutics achieved?
What is the financial condition of Verve Therapeutics?
What is VERVE-101 designed to do?
Who is the CEO of Verve Therapeutics?
What is the significance of Verve's collaboration with Eli Lilly?
What recognition has Verve Therapeutics received?
